Product Description
Pemirolast is a pyrimidinone derivative with anti-allergic activity. Pemirolast blocks the antigen-mediated calcium ion influx into mast cells. This prevents mast cell degranulation, resulting in mast cell stabilization and inhibition of the release of inflammatory mediators, such as histamine and leukotrienes, which are involved in the allergic process. Pemirolast also prevents inflammatory mediator release from eosinophils. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Pemirolast)
Mechanisms of Action: H1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Approved
Approved Countries: Bangladesh | China | Egypt | Hong Kong | Indonesia | Korea | Philippines | Taiwan | Thailand | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: RSPR Pharma AB
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Aortic Aneurysm, Abdominal|Asthma|Muscular Dystrophy, Becker|Muscular Dystrophy, Duchenne|Asthma, Allergic|Abdominal Pain|Coronary Artery Disease|Aortic Rupture
Phase 1: Aortic Aneurysm, Abdominal|Healthy Volunteers